PODCAST EPISODE 311 Click here to watch the video version of this podcast. A college detour from medical school and into scientific research worked to…Read More
In 2018, 4D Molecular Therapeutics announced it was expanding its 2015 research agreement with Roche to develop and commercialize multiple ophthalmology products. This summer, things…Read More
South Korea-based Samsung Bioepis Co. has gained another leg up in the race for an anti-VEGF biosimilar to treat retinal diseases in the lucrative US…Read More
The OIS Index of ophthalmic stocks staged a strong comeback in Q2, gaining 21.4%, in line with the overall US stock market as measured by…Read More
Most transformations are predictable: A caterpillar will turn into a butterfly; a cell will be genetically altered should extraneous DNA enter its membrane. Predictable would…Read More
Now that it has closed on its $63 billion acquisition of Allergan, AbbVie has significantly expanded its revenue base, which could help cushion the blow…Read More
The turmoil in the stock market over the past month or so has sent leading healthcare indices reeling, casting a cloud over the financing that…Read More
The OIS Index of ophthalmic stocks followed global stock markets into bear market territory in Q1, declining 21.2%, in line with the overall US stock…Read More
The explosion of healthcare information technology has engendered a chaotic landscape of infinite terabytes of disparate but mutually relevant data segregated in infinite silos where…Read More
Last week we heard firsthand at OIS@SECO’s second annual event just what it means to be innovative in the field of optometry. Leading off the…Read More
Editor’s Note: The FDA just approved Allergan’s Durysta (bimatoprost implant) 10 mcg for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension on…Read More
As reports of intraocular inflammation and vasculitis have cast caution onto the uptake of the newest approved anti-VEGF drug, Novartis’ Beovu (brolucizumab), the quest to…Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.